Jodts, NielsNielsJodtsWerthen Brabants, LorinLorinWerthen BrabantsAerts, SofieSofieAertsPeeters, Liesbet M.Liesbet M.PeetersVan Wijmeersch, BartBartVan WijmeerschHerzeel, CharlotteCharlotteHerzeelMeertens, ChristelChristelMeertensWuyts, RoelRoelWuytsDhaene, TomTomDhaeneDeschrijver, DirkDirkDeschrijver2026-07-272026-07-2720261664-3224https://imec-publications.be/handle/20.500.12860/60004<jats:sec> <jats:title>Introduction</jats:title> <jats:p>Multiple sclerosis (MS) is an incurable autoimmune disease marked by heterogeneous progression and a lack of reliable biomarkers, complicating prognosis and individualized care. This study introduces a novel trajectory-based statistical approach designed to identify patterns in patient histories within MS populations.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Using longitudinal clinical data from a real-world cohort of 1,025 MS patients (median follow-up: 6.75 years), two complementary analyses were conducted based on patient trajectory analysis. In the first analysis, the technique is applied to the complete dataset after removal of missing values (n = 985; 11,048 events) to uncover latent progressive trajectories. The second analysis evaluated the techniques’ performance on a smaller, limited-sample cohort (n = 83; 282 events).</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p> Across both analyses, the approach revealed previously unrecognized progression patterns, giving rise to new hypotheses, including an effect of Alemtuzumab on the bowel/bladder function (p <jats:italic>&lt;</jats:italic> 0.01, RR = 2.83) and glatiramer acetate on the occurrence of relapses (p <jats:italic>&lt;</jats:italic> 0.01, RR = 1.49). Known associations were also confirmed, such as the relationship between relapse activity and brain lesions (p <jats:italic>&lt;</jats:italic> 0.01, RR = 1.20). </jats:p> </jats:sec> <jats:sec> <jats:title>Discussion</jats:title> <jats:p>The results demonstrate the method’s robustness across varying dataset sizes, highlight its methodological limitations, and show its potential to uncover previously unseen relationships among MS-specific diagnostic events. These findings provide a foundation for generating novel hypotheses relevant to biomarker discovery and therapeutic optimization.</jats:p> </jats:sec>engData-driven hypothesis discovery from disease trajectories in multiple sclerosisJournal article10.3389/fimmu.2026.1758416WOS:001751941600001MEDLINE:42058203